Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: A preliminary report

Indian Heart Journal

Volumn 53, Issue 1, 2001, Pages 74-78

  Gachara, Naomi ^a   Prabhakaran, Suja ^a   Srinivas, Shardha ^a   Farzana, Farida ^a   Krishnan, Usha ^a   Shah, Maully J ^a,b  

^a Madras Medical Mission   (India)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Cardiomyopathy; Carvedilol; Heart failure

Indexed keywords

CAPTOPRIL; CARVEDILOL; DECONGESTIVE AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; SPIRONOLACTONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DILATATION; HEART EJECTION FRACTION; HOSPITALIZATION; HUMAN; INFANT; MALE; PATIENT MONITORING; PRESCHOOL CHILD; TITRIMETRY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; INFANT; MALE; PROPANOLAMINES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0034956483     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Griffin ML, Hernandez A, MartinTC, Goldring D, Bolman RM, Spray TL, et al. Dilated cardiomyopathy in infants and children. J Am Coll Cardiol 1988; 11: 139-144
2. Chen SC, Nouri S, Balfour I, Jureidini S, Appleton S. Clinical profile of congestive cardiomyopathy in children. J Am Coll Cardiol 1990; 15: 189-198
3. Arola A, Tuominen J, Ruuskanen O, Jokinen E. Idiopathic dilated cardiomyopathy in children: prognostic indicators and outcome. Pediatrics 1998; 101: 369-376
4. Burch M, Siddiqui SA, Celermajer DS, Scott C, Bull C, Deanfield JE. Dilated cardiomyopathy in children: determinants of outcome. Br Heart J 1994; 72: 246-250
5. Scammell AM, Arnold R, Wilkinson JL. Captopril in treatment of infant heart failure: a preliminary report. Int J Cardiol 1987; 16: 295-301
6. Kanter KR, Tam VK, Vincent RN, Cuadrado AR, Raviele AA, Berg AM. Current results with pediatric heart transplantation. Ann Thorac Surg 1999; 68: 527-530
7. Morrow WR, Naftel D, Chinnock R, Canter C, Boucek M, Zales V, et al. Outcome of listing for heart transplantation in infants younger than six months: predictors of death and interval to transplantation. The Pediatric Heart Transplantation Study Group. J Heart Lung Transplant 1997; 16: 1255-1266
8. Parisi F, Squitieri C, Carotti A, Abbattista AD, Cicni MP, Esu F, et al. Ten-year follow-up after pediatric transplantation. J Heart Lung Transplant 1999; 18: 275-277
9. Boucek MM, Novick RJ, Bennett LE, Fiol B, Keck BM, Hosenpud JD. The registry of the international society of heart and lung transplantation: second official pediatric report-1998. J Heart Lung Transplant 1998; 17: 1141-1160
10. Shaddy RE, Tani LY, Gidding SS, Pahl E, Orasmond GS, Gilbert EM et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999; 18: 269-274
11. Shaddy RE. Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J 1998; 136: 19-21
12. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yandvitz FD, Bristow MR, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995; 25: 1225-1231
13. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short and long term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical condition in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 1678-1687
14. Packer M, Bristow MR, Cohn J, Colucci WS, Fowler MB, Gilbert EM. et al. The effect of carvedilol on morbity and mortality in patients with chronic heart failure. N Eng J Med 1996; 334: 1349-1355
15. Di Leonarda A, Sabbadini G, Salvatore L, Sinagra G, Mestroni L, Pinamonti B, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999; 33: 1926-1934
16. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DS, et al. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999; 33: 924-931
17. 7. Bistow MR. Carvedilol treatment of chronic heart failure: a new era. Heart (suppl 2) 1998; 79: S31-S34
18. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254
19. Hall SA, Cigarroa CG, Marxoux L, Risser RC, Grayburn PA, Eichhorn EJ, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade, J Am Coll Cardiol 1995; 25: 1154-1161
20. Yoshikawa T, Handa S, Anzai T, Nishimura H, Baba A, Akaishi M, et al. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of β-blocker therapy for congestive heart failure. Am Heart J 1996; 131: 329-335
21. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-2816
22. Australia/New Zealand Heart Failure Research Collaborative Group. Effect of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995; 92: 212-218
23. Sachner-Bernstein J, Krum H, Goldsmith R. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long term treatment (abstr). Circulation 1995; 92 (Suppl 1): 1-395
24. Dzau V, Colucci W, Hollenberg N. Williams G. Relation of the reninangiotensin aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63 645-651
25. Ruffolo RR, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38(Suppl. 2): S82-S88
26. Doughty RN, Whalley GA, Gamble G, MacMhai S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997; 29: 1060-1066
27. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, et al. Prospective randomized comparison of effect of long term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure. Circulation 1999; 99: 2645-2651
28. Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, et al. Efficacy and safety of metoprolol in the treatment of doxorubicin induced cardiomyopathy in pediatric patients. Am Heart J 1995; 129: 197-198
29. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol 1998; 81: 247-250